Laboratory of Molecular Metabolism, The Rockefeller University, New York, New York.
Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.
Am J Physiol Endocrinol Metab. 2023 Feb 1;324(2):E144-E153. doi: 10.1152/ajpendo.00187.2022. Epub 2022 Dec 28.
Although brown fat is strongly associated with a constellation of cardiometabolic benefits in animal models and humans, it has also been tied to cancer cachexia. In humans, cancer-associated cachexia increases mortality, raising the possibility that brown fat in this context may be associated with increased cancer death. However, the effect of brown fat on cancer-associated cachexia and survival in humans remains unclear. Here, we retrospectively identify patients with and without brown fat on fluorodeoxyglucose (F-FDG) positron-emission tomography (PET) scans obtained as part of routine cancer care and assemble a cohort to address these questions. We did not find an association between brown fat status and cachexia. Furthermore, we did not observe an association between brown fat and increased mortality in patients with cachexia. Our analyses controlled for confounding factors including age at cancer diagnosis, sex, body mass index, cancer site, cancer stage, outdoor temperature, comorbid conditions (heart failure, type 2 diabetes mellitus, coronary artery disease, hypertension, dyslipidemia, cerebrovascular disease), and β-blocker use. Taken together, our results suggest that brown fat is not linked to cancer-associated cachexia and does not worsen overall survival in patients with cachexia. This study finds that brown fat is not linked to cancer-associated cachexia. Moreover, this work shows that brown fat does not worsen overall survival in patients with cachexia.
尽管棕色脂肪在动物模型和人类中与一系列心血管代谢益处密切相关，但它也与癌症恶病质有关。在人类中，与癌症相关的恶病质会增加死亡率，这增加了在这种情况下棕色脂肪可能与癌症死亡增加有关的可能性。然而，棕色脂肪对人类癌症相关恶病质和生存的影响仍不清楚。在这里，我们回顾性地确定了在常规癌症治疗中获得的氟脱氧葡萄糖 (F-FDG) 正电子发射断层扫描 (PET) 扫描中存在和不存在棕色脂肪的患者，并组建了一个队列来解决这些问题。我们没有发现棕色脂肪状态与恶病质之间存在关联。此外，我们没有观察到棕色脂肪与恶病质患者死亡率增加之间存在关联。我们的分析控制了混杂因素，包括癌症诊断时的年龄、性别、体重指数、癌症部位、癌症分期、室外温度、合并症（心力衰竭、2 型糖尿病、冠状动脉疾病、高血压、血脂异常、脑血管疾病）和β受体阻滞剂的使用。总之，我们的结果表明，棕色脂肪与癌症相关的恶病质无关，也不会恶化恶病质患者的总生存率。这项研究发现棕色脂肪与癌症相关的恶病质无关。此外，这项工作表明棕色脂肪不会恶化恶病质患者的总生存率。
